Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini Sells 1,562 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini sold 1,562 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $9.15, for a total transaction of $14,292.30. Following the completion of the sale, the chief accounting officer now directly owns 28,189 shares of the company’s stock, valued at approximately $257,929.35. The trade was a 5.25 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Vir Biotechnology Stock Performance

VIR stock opened at $9.65 on Friday. Vir Biotechnology, Inc. has a 1-year low of $6.56 and a 1-year high of $14.45. The business has a 50-day moving average price of $9.13 and a 200 day moving average price of $8.47.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on VIR. Barclays reduced their price target on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. JPMorgan Chase & Co. lifted their target price on Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a research report on Thursday, January 9th. HC Wainwright restated a “buy” rating and issued a $110.00 price target on shares of Vir Biotechnology in a report on Friday, January 31st. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of Vir Biotechnology in a research note on Wednesday, November 20th. Finally, Morgan Stanley raised shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $10.00 to $20.00 in a research report on Thursday, January 9th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Vir Biotechnology presently has an average rating of “Moderate Buy” and a consensus price target of $34.83.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC boosted its stake in shares of Vir Biotechnology by 9.8% during the fourth quarter. Jane Street Group LLC now owns 143,077 shares of the company’s stock valued at $1,050,000 after purchasing an additional 12,730 shares in the last quarter. Northern Trust Corp boosted its position in Vir Biotechnology by 5.9% during the 4th quarter. Northern Trust Corp now owns 930,454 shares of the company’s stock valued at $6,830,000 after acquiring an additional 51,530 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in Vir Biotechnology during the 4th quarter valued at $1,477,000. Nebula Research & Development LLC purchased a new position in shares of Vir Biotechnology in the 4th quarter valued at $84,000. Finally, Syon Capital LLC bought a new position in shares of Vir Biotechnology in the 4th quarter worth $77,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).